Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.

Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.

A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.

A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.

A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy

Phase 3

Terminated

Conditions: Men Who Must Undergo a Prostate Biopsy Related to Prostate Cancer Suspicion.

First Posted Date: 2006-02-22

Last Posted Date: 2009-01-27

Lead Sponsor: Poitiers University Hospital

Target Recruit Count: 300

Registration Number: NCT00294749

Locations: 🇫🇷
Poitiers Hospital University, Poitiers, France

Study of Antibiotics in the Treatment of Colonic Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Metronidazole placebo
Drug: ciprofloxacin
Drug: ciprofloxacin placebo
Drug: metronidazole

First Posted Date: 2005-11-23

Last Posted Date: 2008-08-12

Lead Sponsor: Mount Sinai Hospital, Canada

Target Recruit Count: 12

Registration Number: NCT00257699

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy

Completed

Conditions: Pregnancy

Interventions: Drug: azithromycin
Drug: gentamicin
Drug: ciprofloxacin

First Posted Date: 2005-09-21

Last Posted Date: 2016-10-27

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 150

Registration Number: NCT00214331

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Cefpodoxime vs Ciprofloxacin for Acute Cystitis

Not Applicable

Completed

Conditions: Urinary Tract Infection

Interventions: Drug: Ciprofloxacin
Drug: Cefpodoxime

First Posted Date: 2005-09-19

Last Posted Date: 2014-06-10

Lead Sponsor: University of Washington

Target Recruit Count: 300

Registration Number: NCT00194532

Locations: 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
University of Washington, Seattle, Washington, United States

Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora

Not Applicable

Terminated

Conditions: Healthy Volunteers

First Posted Date: 2005-09-19

Last Posted Date: 2012-09-18

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 48

Registration Number: NCT00190151

Locations: 🇫🇷
Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, Paris, France

Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial

Phase 3

Completed

Conditions: Cholera

First Posted Date: 2005-09-02

Last Posted Date: 2022-02-11

Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Target Recruit Count: 180

Registration Number: NCT00142272

Locations: 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma
Carcinoma of Head/Neck

First Posted Date: 2005-08-31

Last Posted Date: 2008-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00139230

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States